Introduction
============

Pancreatic cancer was the fourth leading cause of cancer-related death in the United States in 2017, with an estimated 53,670 new cases and 43,090 estimated deaths ([@b1-etm-0-0-8795]). The incidence of pancreatic cancer has been on the increase in recent years and it is estimated that it will be the second leading cause of cancer-related death by 2030([@b2-etm-0-0-8795]). Although constituting only approximately 30% volume of the whole pancreas, approximately 70% of pancreatic cancers are located in the head of the pancreas ([@b3-etm-0-0-8795],[@b4-etm-0-0-8795]). Additionally, 20-25% of pancreatic cancers reside in the body and tail of the pancreas ([@b3-etm-0-0-8795]). Previously, several studies reported that patients with pancreatic body/tail cancer had poorer prognosis than patients with head cancer, which was generally attributed to the advanced stages of body/tail cancers upon detection ([@b5-etm-0-0-8795]). However, the different prognosis of patients with head or body/tail pancreatic cancers weighed by stages is largely unidentified. Thus, whether diversities in clinical features exist between head and body/tail pancreatic cancers have not been systematically examined.

The differences between distal and proximal colon cancers in terms of incidence, molecular, immunological, pathological, clinical features, and therapeutic response are well recognized ([@b9-etm-0-0-8795]). The differences have a great impact on the clinical management of colorectal cancer. For example, proximal colon carcinomas were comprised of B-Raf proto-oncogene, and microsatellite instable-high and distal colon carcinomas were more commonly identified in chromosome instable and EGFR or HER2 overexpression ([@b11-etm-0-0-8795]). Additionally, only patients with metastatic distal colon carcinoma were sensitive to anti-EGFR therapy, which is in agreement with the molecular features of distal colon cancers ([@b11-etm-0-0-8795]). However, the differences between head and body/tail pancreatic cancers in terms of incidence, clinical features, and therapeutic response were not systematically analyzed.

The current study was performed to examine the differences in terms of prognosis and incidence between patients with head or body/tail pancreatic cancers using the SEER dataset. In addition, a literature review was performed to identify differences between head and body/tail cancers in terms of embryology, histology, and therapeutic response.

Materials and methods
=====================

### Incidence and survival analysis

The SEER database (1973-2014) was used to collect cases with primary pancreatic adenocarcinoma. Subjects were retrieved using the International Classification of Diseases for Oncology, 3rd editions (ICD-O-3) for tumors of the pancreas. The following tumors of the pancreas were included: 8140/3: adenocarcinoma, nos. Only cases with pathology and/or cytology confirmation were included. Cases with tumor locations of C25.0-head of pancreas, C25.1-body of pancreas, and C25.2-tail of pancreas were included. Patients with ampullary cancer, intraductal papillary mucinous neoplasm, pancreatic neuroendocrine tumor, or adenosquamous carcinoma were excluded. Subjects with multiple primary lesions in the pancreas were excluded. Cases with tumor locations of C25.3-pancreatic duct, C25.4-Islets of Langerhans, C25.7-other specified parts of pancreas, C25.8-overlapping lesion of pancreas, and C25.9-pancreas numbers, were also excluded. Patients with clinical diagnosis only, direct visualization without microscopy, positive laboratory test/marker study, or radiography without microscopic confirmation, were excluded. Subjects with unknown information of follow-up data were also excluded.

The primary examined factor was tumor location. Tumor grade was classified as low (well differentiated), intermediate (moderately differentiated), and high (poorly differentiated or undifferentiated) grade. The 7th edition of American Joint Commission on Cancer Staging (AJCC) staging system for pancreatic cancer was used ([@b15-etm-0-0-8795]). Informed consent was waived in the study. The study protocol was approved by the ethics committee of Fundan University Shanghai Cancer Center.

### Literatures review

Available literature about differences in embryology and histology between head and body/tail pancreas was reviewed. Additionally, a search was conducted for literature concerning the clinical presentation of pancreatic cancers divided by primary tumor locations. The response of pancreatic cancers to therapeutic modalities including systemic and adjuvant chemotherapy by site was also reviewed.

### Statistical analysis

The distribution of categorical variables was assessed by Pearson\'s χ^2^ test by tumor locations (head vs body/tail pancreatic cancers). Continuous variables were examined by Student\'s t-test or rank sum tests. Comparison of overall survival between head and body/tail pancreatic cancers was performed for all stages combined and within each stage (i.e., stages I to IV) by univariate Kaplan-Meier survival analysis and log-rank test. Adjusted HRs and 95% CIs were examined by Cox proportional hazards regression analysis. Statistical analysis was assessed using STATA 12.0 software (STATA, College Station). Statistical significance was considered as two-sided P\<0.05.

Results
=======

### Patient characteristics

In total, 85,715 patients were retrieved from the SEER database, including 60,015 (70.0%) patients with head pancreatic tumor and 25,700 (30.0%) patients with body/tail tumor ([Table I](#tI-etm-0-0-8795){ref-type="table"}). The size of body/tail tumor was larger than that of head tumor (mean size, 4.6 vs. 3.8 cm, P\<0.001). Body/tail pancreatic tumor had a higher proportion of high-grade tumors (poorly differentiated or undifferentiated) than that of head tumor (49.6 vs. 44.4%, P\<0.001). For resected tumors, body/tail tumor had less lymph nodes harvested than head tumor (median number, 7 vs. 10, P\<0.001). Body/tail cancer had lower proportion of T1/T2 tumors (24.2%) than that of head cancer (35.2%, P\<0.001). The proportion of metastatic tumor was higher in body/tail pancreatic cancer (79.4%) than that in head cancer (46.3%) and the surgical resection rate of body/tail cancer (9.4%) was lower than that of head cancer (20.4%).

### Survival analysis

Overall, patients with body/tail pancreatic cancer had poorer prognosis than patients with head cancer (unadjusted HR, 1.28, 95% CI, 1.26-1.30, P\<0.001, [Fig. 1](#f1-etm-0-0-8795){ref-type="fig"}; adjusted HR, 1.03, 95% CI, 1.00-1.05, P=0.025, [Table II](#tII-etm-0-0-8795){ref-type="table"}). For stage I disease, patients with body/tail cancer had superior prognosis compared with patients with head cancer (adjusted HR, 0.85, 95% CI, 0.76-0.94, P=0.001; [Fig. 2A](#f2-etm-0-0-8795){ref-type="fig"}). For stage II/III disease, no statistical significance was found between patients with body/tail cancer and patients with head cancer \[stage II, adjusted HR, 1.00, 95% CI, 0.95-1.06, P=0.965 ([Fig. 2B](#f2-etm-0-0-8795){ref-type="fig"}); stage III, 0.97, 95% CI, 0.91-1.04, P=0.398 ([Fig. 2C](#f2-etm-0-0-8795){ref-type="fig"}) ([Table II](#tII-etm-0-0-8795){ref-type="table"})\]. For stage IV disease, patients with body/tail cancer had poorer prognosis than patients with head cancer (adjusted HR, 1.07, 95% CI, 1.04-1.10, P\<0.001; [Table II](#tII-etm-0-0-8795){ref-type="table"}). The proportion of body/tail tumor showed a steady increase from 24.9% in 1973 to 36.3% in 2014, with an annual increasing rate of 0.27% ([Fig. 3](#f3-etm-0-0-8795){ref-type="fig"}).

### Literature review

A systematic literature review was performed to identify potential differences between body/tail and head pancreas and pancreatic cancers, which is summarized in [Fig. 4](#f4-etm-0-0-8795){ref-type="fig"}. The ventral pancreas forms the posterior part of the head of the pancreas and the uncinate process, while the dorsal pancreas forms the body and tail of the pancreas and the anterior part of the head of the gland ([@b16-etm-0-0-8795]). The ventral pancreas has macroscopic, microscopic and molecular features differing from the dorsal pancreas ([@b16-etm-0-0-8795],[@b17-etm-0-0-8795]). In addition, islets mainly reside in the body/tail of the pancreas ([@b18-etm-0-0-8795]). Patients with body/tail cancer usually undergo distal pancreatectomy and experience less jaundice, while patients with head cancer typically undergo pancreaticoduodenectomy and exhibit more jaundice ([@b3-etm-0-0-8795],[@b19-etm-0-0-8795]). Previous findings have shown the adjuvant and systemic chemotherapy for pancreatic cancer by anatomic sites ([@b20-etm-0-0-8795]). For body/tail pancreatic cancer, metastatic diseases were sensitive to Nanoliposomal irinotecan, 5-FU/Leucovorin (Nanoliposomal irinotecan, 5-FU/Leucovorin vs. 5-FU/Leucovorin, HR, 0.51, 95% CI, 0.31-0.85) ([@b23-etm-0-0-8795]) and resected diseases were sensitive to both S-1 and Gemcitabine (S-1 vs. Gemcitabine, HR, 0.59, 95% CI, 0.37-0.94) ([@b21-etm-0-0-8795]). For head pancreatic cancer, metastatic diseases were sensitive to Nab-Paclitaxel plus Gemcitabine (Nab-Paclitaxel plus Gemcitabine vs. Gemcitabine, HR, 0.59, 95% CI, 0.46-0.75) ([@b22-etm-0-0-8795]) and resected diseases were sensitive to Gemcitabine (Gemcitabine vs. 5-FU, HR, 0.80, 95% CI, 0.63-1.00) ([@b24-etm-0-0-8795]).

Discussion
==========

It is well known that the majority of pancreatic cancers reside in the head of the pancreas and that body/tail pancreatic cancers are less common ([@b3-etm-0-0-8795],[@b19-etm-0-0-8795]). However, we found that the proportion of head pancreatic cancer was steadily decreased from 75.1 to 63.7% and the proportion of body/tail cancer was gradually increased from 24.9 to 36.3% according to the SEER database from 1973 to 2014. The increased proportion of body/tail pancreatic may be attributed to the wide use of modern detection methods. Notably, a similar trend occurred in colorectal cancer, with the incidence of proximal colorectal cancer mildly decreasing (-6.37%) and distal colorectal cancer obviously decreasing (-37.79%) from 1976 to 2005 based on the SEER database ([@b25-etm-0-0-8795]).

Patients with body/tail pancreatic cancer usually have worse outcome than patients with head cancer, which is largely attributed to the fact that body/tail pancreatic cancers typically present at a more advanced stage than head cancers ([@b5-etm-0-0-8795],[@b6-etm-0-0-8795],[@b26-etm-0-0-8795]). Our study confirms that body/tail cancers had a higher proportion of metastatic diseases than head cancers (75.6 vs. 42.3%). However, when controlled for stages and other prognostic factors, patients with body/tail pancreatic cancer still had worse prognosis than patients with head cancer. Moreover, body/tail pancreatic cancers showed lower mortality for stage I cancers, no significant difference in mortality for stages II and III, and a higher mortality for stage IV cancer compared with head cancers by adjusted Cox regression, indicating that the biology of body/tail cancers is different from that of head cancers. Of note, right-sided colon cancers also had a worse outcome than left-sided ones ([@b14-etm-0-0-8795]). In addition, within stage I, no difference in prognosis was observed between right- and left-sided colon cancers; within stage II disease, right-sided cancers had an improved outcome; within stage III, right-sided cancers had worse outcome ([@b12-etm-0-0-8795]).

For body/tail pancreatic cancer, metastatic diseases were sensitive to Nanoliposomal irinotecan, 5-FU/Leucovorin and resected diseases were sensitive to adjuvant S-1 or Gemcitabine ([@b21-etm-0-0-8795],[@b23-etm-0-0-8795]). For head pancreatic cancer, metastatic diseases were sensitive to Nab-Paclitaxel plus Gemcitabine and resected diseases were sensitive to adjuvant Gemcitabine ([@b22-etm-0-0-8795],[@b24-etm-0-0-8795]). Those findings indicate that pancreatic head cancers may be sensitive to Gemcitabine-based regimen and body/tail cancers may be sensitive to 5-FU based regimen. However, future studies concerning the response to systematic therapy divided by tumor locations are needed.

This study systematically demonstrated that major differences exist between head and body/tail pancreatic cancers in terms of incidence, prognosis, molecular characteristics, embryology and histology, clinical presentation and therapeutic response. These diversities between head and body/tail pancreatic cancers may have a great impact on clinical management. However, in spite of employing a well-recognized public database and systematically reviewing the literature, the current study was mainly limited by its retrospective nature. Further studies are imperative to identify potential molecular diversities between head and body/tail pancreatic cancers and explore therapeutic potential. Prospective clinical trials regarding the different therapeutic response between head and body/tail pancreatic cancers are required.
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![Kaplan-Meier curves of overall survival and log-rank test for patients with pancreatic cancer by anatomic subsites of head and body/tail using the SEER registry for the period 1973-2014. Patients with body/tail tumor had worse outcome than patients with head tumor (HR=1.28, P\<0.001).](etm-20-02-1091-g00){#f1-etm-0-0-8795}

![Kaplan-Meier curves of overall survival and log-rank tests for patients with pancreatic cancer divided by anatomic subsites and tumor stages. For stage IV diseases (D), patients with body/tail tumor had worse outcome than patients with head tumor. However, for stage I disease (A), patients with body/tail tumor had better outcome than patients with head tumor. No statistical difference in overall survival was observed for patients with stage II (B) or III (C) disease.](etm-20-02-1091-g01){#f2-etm-0-0-8795}

![Percentage trends of pancreatic cancer by anatomic subsites of head and body/tail using the SEER registry 1973 to 2014. The percentage of body/tail tumors increased from 24.9 to 36.3% and head tumor decreased from 75.1 to 63.7%.](etm-20-02-1091-g02){#f3-etm-0-0-8795}

![Summary of diversities between head and body/tail pancreatic cancers. Major differences were observed in embryology and histology, incidence, presentation, outcome, and treatment.](etm-20-02-1091-g03){#f4-etm-0-0-8795}

###### 

Characteristics of patients with head and body/tail pancreatic cancer.

  Characteristics                                                       Overall (n=85,715)   Head (n=60,015)   Body/tail (n=25,700)   P-value
  --------------------------------------------------------------------- -------------------- ----------------- ---------------------- ---------
  Survival (months), median                                             6.0                  7.0               5.0                    \<0.001
  Sex                                                                                                                                 \<0.001
       Male (%)                                                         43,925 (51.2)        30,190 (50.3)     13,735 (53.4)           
       Female (%)                                                       41,790 (48.8)        29,825 (49.7)     11,965 (46.6)           
  Age (years)                                                                                                                         \<0.001
       Mean ± SD                                                        68.2±11.5            68.4±11.6         67.7±11.3               
  Race (%)                                                                                                                            \<0.001
       Caucasian                                                        69,663 (81.3)        49,035 (81.7)     20,628 (80.3)           
       African descent                                                  10,368 (12.1)        7,136 (11.9)      3,232 (12.6)            
       Others                                                           5,684 (6.6)          3,844 (6.4)       1,840 (7.2)             
  Tumor size (cm)                                                       n=40,677             n=26,778          n=13,899               \<0.001
       Mean ± SD                                                        4.0±2.8              3.8±2.7           4.6±2.9                 
  Surgical resection                                                    83,568               58,408            25,160                 \<0.001
       Yes (%)                                                          14,304 (17.1)        11,930 (20.4)     2,374 (9.4)             
       No (%)                                                           69,264 (82.9)        46,478 (79.6)     22,786 (90.6)           
  Tumor grade (%)                                                       35,691               26,847            8,844                  \<0.001
       Low                                                              4,680 (13.1)         3,721 (13.9)      959 (10.8)              
       Intermediate                                                     14,706 (41.2)        11,211 (41.8)     3,495 (39.5)            
       High                                                             16,305 (45.7)        11,915 (44.4)     4,390 (49.6)            
  No. of nodes resected^[a](#tfn1-etm-0-0-8795){ref-type="table-fn"}^   12,553               10,470            2,083                  \<0.001
       Median                                                           10                   10                7                       
       95% CI                                                           (9, 10)              (10, 10)          (6, 7)                  
  T stage                                                               40,956               27,904            13,052                 \<0.001
       T1                                                               1,553 (3.8)          1,110 (4.0)       443 (3.4)               
       T2                                                               9,789 (23.9)         5,637 (20.2)      4,152 (31.8)            
       T3                                                               19,912 (48.6)        15,194 (54.5)     4,718 (36.1)            
       T4                                                               9,702 (23.7)         5,963 (21.4)      3,739 (28.6)            
  Nodal status                                                          41,382               28,112            13,270                 \<0.001
       N0                                                               25,059 (60.6)        16,498 (58.7)     8,561 (64.5)            
       N1                                                               16,323 (39.4)        11,614 (41.3)     4,709 (35.5)            
  Distant metastasis                                                    81,832               56,858            24,974                 \<0.001
       M0                                                               35,712 (43.6)        30,556 (53.7)     5,156 (20.6)            
       M1                                                               46,120 (56.4)        26,302 (46.3)     19,818 (79.4)           
  Stage^[b](#tfn2-etm-0-0-8795){ref-type="table-fn"}^                   45,406               29,676            15,730                 \<0.001
       I                                                                3,132 (6.9)          2,475 (8.3)       657 (4.2)               
       II                                                               12,894 (28.4)        11,118 (37.5)     1,776 (11.3)            
       III                                                              4,949 (10.9)         3,544 (11.9)      1,405 (8.9)             
       IV                                                               24,431 (53.8)        12,539 (42.3)     11,892 (75.6)           

^a^For resected cases only;

^b^For cases with information of AJCC 7th stage.

###### 

Multivariate analysis of prognostic factors.

                         All stages         Stage I   Stage II           Stage III   Stage IV                                                                     
  ---------------------- ------------------ --------- ------------------ ----------- ------------------ --------- ------------------ --------- ------------------ ---------
  Age, years                                                                                                                                                      
       ≤70               1                            1                              1                            1                            1                   
       \>70              1.41 (1.38-1.44)   \<0.001   1.54 (1.41-1.69)   \<0.001     1.46 (1.40-1.52)   \<0.001   1.44 (1.35-1.54)   \<0.001   1.33 (1.30-1.37)   \<0.001
  Sex                                                                                                                                                             
       Male              1                            1                              1                            1                            1                   
       Female            0.95 (0.93-0.97)   \<0.001   0.98 (0.90-1.06)   0.623       0.96 (0.93-1.00)   0.067     0.89 (0.83-0.94)   \<0.001   0.95 (0.93-0.98)   0.001
  Race (%)                                                                                                                                                        
       Caucasian         1                            1                              1                            1                            1                   
       African descent   1.17 (1.13-1.21)   \<0.001   1.14 (1.01-1.29)   0.037       1.13 (1.06-1.21)   \<0.001   1.13 (1.03-1.24)   0.010     1.18 (1.13-1.23)   \<0.001
       Others            1.00 (0.96-1.05)   0.863     0.92 (0.78-1.09)   0.327       1.04 (0.96-1.12)   0.350     0.99 (0.88-1.11)   0.818     1.00 (0.95-1.06)   0.876
  Grade                                                                                                                                                           
       Low               1                            1                              1                            1                            1                   
       Medium            1.13 (1.07-1.20)   \<0.001   1.33 (1.09-1.62)   0.005       1.02 (0.93-1.12)   0.645     1.18 (1.01-1.39)   0.042     1.24 (1.11-1.38)   \<0.001
       High              1.50 (1.41-1.60)   \<0.001   1.85 (1.51-2.27)   \<0.001     1.32 (1.21-1.45)   \<0.001   1.73 (1.48-2.04)   \<0.001   1.53 (1.38-1.71)   \<0.001
  Stage                                                                                                                                                           
       I                 1                            /                              /                            /                            /                   
       II                1.05 (1.00-1.09)   0.053     /                              /                            /                            /                   
       III               1.33 (1.26-1.40)   \<0.001   /                              /                            /                            /                   
       IV                2.25 (2.15-2.35)   \<0.001   /                              /                            /                            /                   
  Location                                                                                                                                                        
       Head              1                            1                              1                            1                            1                   
       Body/tail         1.03 (1.00-1.05)   0.025     0.85 (0.76-0.94)   0.001       1.00 (0.95-1.06)   0.965     0.97 (0.91-1.04)   0.398     1.07 (1.04-1.10)   \<0.001

[^1]: ^\*^Contributed equally
